Dr. Scott Rocklage’s Path to a Successful Healthcare Executive

Dr. Scott Rocklage has amassed over 30 years’ experience in healthcare management. His success in the chemical industry is mainly backed by his strong academic background and leadership abilities. Dr. Rocklage attained his B.S. in chemistry undergraduate degree from the University of California, Berkeley. He also holds a Ph.D. in chemistry from the Massachusetts Institute of Technology.

Throughout his career, Rocklage has worked for both small and big players in the biotechnology industry. Currently, he is the managing partner of 5AM Ventures, a venture capital company that supports emerging life science firms. He first joined as venture partner in 2003; a year later the company appointed him to be a managing partner. Between May to July 2016, Dr. Rocklage was at the helm of EPIRUS Biopharmaceuticals, Inc. as the Chief Executive Officer. In addition, he had a stint at Cubist Pharmaceuticals, a publicly-traded company, and Nycomed Salutar, a company that specializes in diagnostic imaging as Chairman and CEO. Dr. Rocklage’s work experience is further enhanced by R&D positions he served at Nycomed and Catalytica between 1986 and 1989.While working in R&D, he was able to innovate and develop high-end products.

Currently, apart from serving as a chairman of the board of directors in Rennovia, Inc., Dr. Rocklage also serves Achaogen, Inc. in the same capacity. Rennovia is a private company with specialty in bio-renewable chemicals and medical technology firm Kinestral Technologies. Besides, Rocklage serves as the Board Chairman of WaveRx, Relypsa, Semprus, Variation and Pulmatrix. He is also a member of Board of Associates at the Whitehead Institute. Previously, Rocklage served as the Executive Chairman of Miikana (acquired by EntreMed) and Ilypsa (acquired by Amgen).

The vast experience and leadership capabilities that Dr. Rocklage has gained in the management of healthcare companies helped him to successfully lead the development of Cubicin (an antibiotic treatment) by Cubist Pharmaceuticals, Inc., and its subsequent approval by FDA. He is also the lead man in the development and FDA approval of Omniscan™ and Teslascan® drugs manufactured by Nycomed Salutar, Inc. Also, Scott Rocklage has gained a good reputation in helping several drug candidates gain approval for clinical trials. He has over 30 US invention patents, and published over 100 peer reviewed articles.

While at Massachusetts Institute of Technology for PhD studies, Dr. Rocklage researched under Richard R. Schrock’s laboratory named after chemistry professor and Nobel Prize winner in Chemistry. His attachment to MIT helped him establish a strong, professional life and career. Scott Rocklage together with his loving wife offered to donate $250,000 for the revamping of Nano chemistry and nanotechnology lab space in Building 2. Indisputably, Rocklage is a success story in turning science into business. He has contributed a lot to the Science sector throughout his career.

Leave a Reply

Your email address will not be published. Required fields are marked *


Hi, guest!